211 related articles for article (PubMed ID: 24349380)
41. Angiopoietins in the bone marrow microenvironment of acute lymphoblastic leukemia.
Karakurt N; Aksu T; Koksal Y; Yarali N; Tunc B; Uckan-Cetinkaya D; Ozguner M
Hematology; 2016 Jul; 21(6):325-31. PubMed ID: 26901808
[TBL] [Abstract][Full Text] [Related]
42. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
43. [Initial response to therapy as an important prognostic factor in acute lymphoblastic leukemia in childhood. COALL study group].
Janka-Schaub GE; Stührk H; Kortüm B; Graubner U; Jürgens H; Spaar HJ; Schöck V; Dohrn B; Bahr R; Winkler K
Klin Padiatr; 1991; 203(4):231-5. PubMed ID: 1942930
[TBL] [Abstract][Full Text] [Related]
44. Biological, functional and genetic characterization of bone marrow-derived mesenchymal stromal cells from pediatric patients affected by acute lymphoblastic leukemia.
Conforti A; Biagini S; Del Bufalo F; Sirleto P; Angioni A; Starc N; Li Pira G; Moretta F; Proia A; Contoli B; Genovese S; Ciardi C; Avanzini MA; Rosti V; Lo-Coco F; Locatelli F; Bernardo ME
PLoS One; 2013; 8(11):e76989. PubMed ID: 24244271
[TBL] [Abstract][Full Text] [Related]
45. Blast Percentage of Bone Marrow Aspirate on Day 14 of Induction Chemotherapy Predicts Adult Acute Lymphoblastic Leukemia Treatment Outcomes.
Park HS; Kim DY; Choi EJ; Lee JH; Lee JH; Jeon M; Kang YA; Lee YS; Seol M; Cho YU; Jang S; Chi HS; Lee KH; Park CJ
Acta Haematol; 2018; 139(4):220-227. PubMed ID: 29860259
[TBL] [Abstract][Full Text] [Related]
46. Cytokines, growth, and environment factors in bone marrow plasma of acute lymphoblastic leukemia pediatric patients.
Kováč M; Vášková M; Petráčková D; Pelková V; Mejstříková E; Kalina T; Žaliová M; Weiser J; Starý J; Hrušák O
Eur Cytokine Netw; 2014 Mar; 25(1):8-13. PubMed ID: 24998352
[TBL] [Abstract][Full Text] [Related]
47. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.
Scheuring UJ; Pfeifer H; Wassmann B; Brück P; Gehrke B; Petershofen EK; Gschaidmeier H; Hoelzer D; Ottmann OG
Leukemia; 2003 Sep; 17(9):1700-6. PubMed ID: 12970767
[TBL] [Abstract][Full Text] [Related]
48. A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.
Samuels AL; Beesley AH; Yadav BD; Papa RA; Sutton R; Anderson D; Marshall GM; Cole CH; Kees UR; Lock RB
Blood Cancer J; 2014 Aug; 4(8):e232. PubMed ID: 25083816
[TBL] [Abstract][Full Text] [Related]
49. Detection of neuroblastoma cells in bone marrow and peripheral blood by different techniques: accuracy and relationship with clinical features of patients.
Corrias MV; Faulkner LB; Pistorio A; Rosanda C; Callea F; Piccolo MS; Scaruffi P; Marchi C; Lacitignola L; Occhino M; Gambini C; Tonini GP; Haupt R; De Bernardi B; Pistoia V; Garaventa A
Clin Cancer Res; 2004 Dec; 10(23):7978-85. PubMed ID: 15585633
[TBL] [Abstract][Full Text] [Related]
50. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.
Miller DR; Coccia PF; Bleyer WA; Lukens JN; Siegel SE; Sather HN; Hammond GD
J Clin Oncol; 1989 Dec; 7(12):1807-15. PubMed ID: 2685179
[TBL] [Abstract][Full Text] [Related]
51. The combination of four analytical methods to explore skeletal muscle metabolomics: Better coverage of metabolic pathways or a marketing argument?
Bruno C; Patin F; Bocca C; Nadal-Desbarats L; Bonnier F; Reynier P; Emond P; Vourc'h P; Joseph-Delafont K; Corcia P; Andres CR; Blasco H
J Pharm Biomed Anal; 2018 Jan; 148():273-279. PubMed ID: 29059617
[TBL] [Abstract][Full Text] [Related]
52. Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.
Koh KN; Im HJ; Kim H; Kang HJ; Park KD; Shin HY; Ahn HS; Lee JW; Yoo KH; Sung KW; Koo HH; Lim YT; Park JE; Park BK; Park HJ; Seo JJ
J Korean Med Sci; 2017 Apr; 32(4):642-649. PubMed ID: 28244291
[TBL] [Abstract][Full Text] [Related]
53. Prognostic value of persistent peripheral blood and bone marrow lymphoblasts on day 15 of therapy in childhood acute lymphoblastic leukemia as detected by flow cytometry.
Jaworska-Posadzy A; Styczynski J; Kubicka M; Debski R; Rafinska-Kurylo B; Kolodziej B; Pogorzala M; Wysocki M
Anticancer Res; 2011 Apr; 31(4):1453-7. PubMed ID: 21508402
[TBL] [Abstract][Full Text] [Related]
54. Minimal residual disease in acute lymphoblastic leukaemia--PCR analysis of immunoglobulin gene rearrangements.
Cole-Sinclair M; Foroni L; Wright F; Mehta A; Prentice HG; Hoffbrand AV
Leuk Lymphoma; 1993; 11 Suppl 2():49-58. PubMed ID: 8124233
[TBL] [Abstract][Full Text] [Related]
55. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
[TBL] [Abstract][Full Text] [Related]
56. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features.
Gaynon PS; Bleyer WA; Steinherz PG; Finklestein JZ; Littman P; Miller DR; Reaman G; Sather H; Hammond GD
Med Pediatr Oncol; 1990; 18(4):273-9. PubMed ID: 2355886
[TBL] [Abstract][Full Text] [Related]
57. IGFBP7 participates in the reciprocal interaction between acute lymphoblastic leukemia and BM stromal cells and in leukemia resistance to asparaginase.
Laranjeira AB; de Vasconcellos JF; Sodek L; Spago MC; Fornazim MC; Tone LG; Brandalise SR; Nowill AE; Yunes JA
Leukemia; 2012 May; 26(5):1001-11. PubMed ID: 22005787
[TBL] [Abstract][Full Text] [Related]
58. [Clinical features and prognosis of children with lymphoblastic lymphoma].
Jin L; Zhang R; Huang S; Yang J; Duan YL; Zhang YH
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):138-42. PubMed ID: 22780934
[TBL] [Abstract][Full Text] [Related]
59. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; Camitta BM
J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277
[TBL] [Abstract][Full Text] [Related]
60. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
